Dopaminergic challenges in social anxiety disorder: evidence for dopamine D3 desensitisation following successful treatment with serotonergic antidepressants.

@article{Hood2010DopaminergicCI,
  title={Dopaminergic challenges in social anxiety disorder: evidence for dopamine D3 desensitisation following successful treatment with serotonergic antidepressants.},
  author={Sean David Hood and John P. Potokar and Simon J. C. Davies and Dana Adelle Hince and Kelly Morris and Kate Seddon and David J. Nutt and Spilios V. Argyropoulos},
  journal={Journal of psychopharmacology},
  year={2010},
  volume={24 5},
  pages={709-16}
}
Serotonergic antidepressants (SSRIs) are first-line treatments for social anxiety disorder [SAnD], though there is evidence of dopaminergic system dysfunction. Twenty subjects with DSM-IV SAnD, untreated (n = 10) and SSRI-remitted DSM-IV SAnD (n = 10), were administered a single dose of 1) a dopamine agonist (pramipexole 0.5 mg) and 2) a dopamine antagonist (sulpiride 400 mg), followed by anxiogenic challenges (verbal tasks and autobiographical scripts) in a double-blind crossover design, the… CONTINUE READING